Article
Rheumatology
Philip S. Helliwell, Phillip J. Mease, Arthurl Kavanaugh, Laura C. Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, Lyrica X. H. Liu, David Collier, Dafna D. Gladman
Summary: The presence of dactylitis and nail disease is associated with improved outcomes in patients with early PsA who were treated with methotrexate and/or etanercept, while enthesitis is not.
Article
Rheumatology
Paolo Gisondi, Francesco Bellinato, Giovanni Targher, Luca Idolazzi, Giampiero Girolomoni
Summary: In patients with moderate-to-severe chronic plaque psoriasis, treatment with bDMARDs may delay or reduce the risk of incident PsA. The annual incidence rate of PsA was significantly lower in the bDMARDs group compared to the phototherapy group. Factors associated with a higher risk of PsA included older age, nail psoriasis, and psoriasis duration over 10 years.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Pharmacology & Pharmacy
Ko-Jen Li, Chia-Li Chang, Chih-Yi Hsin, Chao-Hsiun Tang
Summary: This study found that TNFi were the preferred agents for RA treatment during 2012-2017. Non-TNFi and tofacitinib were common second-line agents being switched to. Nearly half of discontinued patients received retreatment, with a majority receiving the same agent.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Rheumatology
Akira Onishi, Hirotaka Yamada, Wataru Yamamoto, Ryu Watanabe, Ryota Hara, Masaki Katayama, Yasutaka Okita, Yuichi Maeda, Hideki Amuro, Yonsu Son, Ayaka Yoshikawa, Kenichiro Hata, Motomu Hashimoto, Jun Saegusa, Akio Morinobu
Summary: This study aimed to evaluate the effectiveness and drug tolerability of biological DMARD (bDMARD) and Janus kinase inhibitor (JAKi) monotherapy in patients with rheumatoid arthritis (RA). The study found that IL-6Ri monotherapy was superior to TNFi monotherapy in terms of effectiveness and drug retention, while no significant differences were identified between CTLA4Ig and JAKi monotherapy and TNFi monotherapy.
Article
Rheumatology
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda
Summary: Based on primary results from ORAL Surveillance, this study identified two subpopulations of patients treated with tofacitinib who had different relative risks compared to TNFi. Older age and smoking were identified as risk factors associated with increased risk, while younger age and non-smoking were associated with no detectable risk increase. These findings have important implications for individualized treatment decisions with tofacitinib.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Xenofon Baraliakos, Laure Gossec, Effie Pournara, Slawomir Jeka, Antonio Mera-Varela, Salvatore D'Angelo, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella, Laura C. Coates
Summary: The MAXIMISE trial demonstrated that secukinumab significantly improved axial disease symptoms in patients with PsA, particularly those with inadequate response to NSAIDs.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Andra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L. Bhatt, Carol A. Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B. Shapiro, Janet E. Pope, Hendrik Schulze-Koops
Summary: This study aimed to characterize infections in patients with rheumatoid arthritis (RA) receiving different treatment regimens. The results showed that tofacitinib had a higher risk of infections compared to tumor necrosis factor inhibitors (TNFi). These findings may provide insights for future treatment decisions.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Esther Beckers, Annelies Boonen, Astrid van Tubergen
Summary: We developed a web-based evidence-based decision aid to support shared decision-making in patients with axial spondyloarthritis (axSpA) who face a treatment decision to initiate or switch a biological or targeted synthetic disease modifying antirheumatic drug (b/tsDMARDs). The decision aid was developed through an iterative process based on evidence from the literature, needs assessment interviews, and expert input. The decision aid was then introduced in clinical practice through a multifaceted strategy.
Article
Rheumatology
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Elke Theander, Josef S. Smolen
Summary: In the real-world treatment of psoriatic arthritis, ustekinumab and TNFi demonstrate comparable overall treatment persistence, effectiveness, and safety.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles-Schoeman, Eduardo Mysler, Kunihiro Yamaoka, Christophe Richez, Hannah Palac, Deanne Dilley, Jianzhong Liu, Sander Strengholt, Gerd Burmester
Summary: A post hoc analysis was conducted to assess the potential risk of upadacitinib in a high-risk population of patients with rheumatoid arthritis (RA). The results showed that while there was an increased risk of major adverse cardiovascular events (MACE), malignancy (excluding non-melanoma skin cancer), and venous thromboembolism (VTE) in the high-risk populations, the risk was comparable between upadacitinib-treated and adalimumab-treated patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Jeffrey R. Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L. Bhatt, Levent M. Gunay, Naonobu Sugiyama, Carol A. Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J. Gomez-Reino
Summary: This study evaluated malignancies and their associations with baseline risk factors and cardiovascular risk scores in patients with rheumatoid arthritis (RA) treated with tofacitinib and tumour necrosis factor inhibitors (TNFi). The results showed that the risk of malignancies was increased with tofacitinib compared to TNFi, and the highest incidence was observed in patients with a history of atherosclerotic cardiovascular disease (HxASCVD) or increasing cardiovascular risk.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Namrata Singh, Christopher Li
Summary: Most studies have not found an association between tumor necrosis factor inhibitors (TNFi) and risk of incident cancer in patients with rheumatoid arthritis (RA). Limited research suggests that non-TNFi biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs also do not increase the risk of cancer, but further studies are needed to confirm these findings.
CURRENT OPINION IN RHEUMATOLOGY
(2021)
Article
Rheumatology
Yu-Jih Su, Hui-Ming Chen, Tien-Ming Chan, Tien-Tsai Cheng, Shan-Fu Yu, Jia-Feng Chen, Chun-Yu Lin, Chung-Yuan Hsu
Summary: This study aimed to investigate whether patients using disease-modifying anti-rheumatic drugs (DMARDs) may have different levels of risk for diabetes and to analyze other risk factors for diabetes. The results showed that certain DMARDs can reduce the risk of diabetes.
Article
Rheumatology
Katelyn Baggett, Timothy G. Brandon, Rui Xiao, Zachary Valenzuela, Lisa H. Buckley, Pamela F. Weiss
Summary: The study found no significant difference in the risk of developing psoriasis after treatment with ADA, IFX, or ETN among children who received TNFi therapy. However, the risk of psoriasis was significantly lower in patients who were also exposed to DMARDs.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Pharmacology & Pharmacy
Ronaldo Jose Faria, Francisca Janiclecia Rezende Cordeiro, Jessica Barreto Ribeiro dos Santos, Juliana Alvares-Teodoro, Augusto Afonso Guerra Junior, Francisco de Assis Acurcio, Michael Ruberson Ribeiro da Silva
Summary: This study compared the use of conventional synthetic disease-modifying antirheumatic drugs in the treatment of psoriatic arthritis. The results showed that methotrexate was the most frequently used drug, with lower cost and slightly lower persistence, making it the drug with the best cost per response ratio.
FRONTIERS IN PHARMACOLOGY
(2022)
Editorial Material
Rheumatology
Ying-Ying Leung
JOURNAL OF RHEUMATOLOGY
(2022)
Meeting Abstract
Rheumatology
A. Singh, P. Molina-Garcia, S. Hussain, A. Paul, S. K. Das, Y. Y. Leung, J. Samuels, B. Antony
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Rheumatology
Ambrish Singh, Pablo Molina-Garcia, Salman Hussain, Alok Paul, Siddharth Kumar Das, Ying-Ying Leung, Catherine L. Hill, Debashish Danda, Jonathan Samuels, Benny Antony
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of colchicine for the treatment of osteoarthritis (OA). The study found that colchicine did not show significant benefits in reducing pain and improving physical function compared to placebo or other active comparators. The results suggest that future trials should focus on subgroups of OA patients with inflammation and mineralization who might benefit from colchicine.
CLINICAL RHEUMATOLOGY
(2023)
Review
Rheumatology
Ying-Ying Leung, Tatiana V. Korotaeva, Liliana Candia, Susanne Juhl Pedersen, Wilson Bautista Molano, Eric M. Ruderman, Radjesh Bisoendial, Rodolfo Perez-Alamino, Wendy Olsder, Burkhard Moeller, Simeon Grazio, Tania Gudu, Girish M. Mody, Carlos Pineda, Helena Raffayova, Sherry Rohekar, Claudia Goldenstein-Schainberg, Sergio R. Gutierrez Urena, Julio Cesar Casasola Vargas, Bhowmik Meghnathi, Roopa Prasad, Pascal Richette, Jose Roberto S. Miranda, Nikolas Malliotis, Ulla Lindqvist, David Simon, Amara Ezeonyeli, Enrique R. Soriano, Oliver FitzGerald
Summary: The objective of this study was to provide evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of PsA for the revised 2021 GRAPPA treatment recommendations. Evidence was derived from new RCTs and recommendations were made for different patient groups based on their treatment history and response. Different classes of therapeutic options were strongly recommended for different patient groups.
JOURNAL OF RHEUMATOLOGY
(2023)
Editorial Material
Rheumatology
Pei-En Kao, Yung-Heng Lee, Kevin Sheng-Kai Ma, Amy Ker, Ying-Ying Leung
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Immunology
Margaret Ma, Amelia Santosa, Warren Fong, Li-Ching Chew, Andrea H. L. Low, Annie Law, Yih Jia Poh, Siaw Ing Yeo, Ying Ying Leung, Victoria W. W. Ng, Joshua Z. E. Koh, Sen Hee Tay, Anselm Mak, Gim Gee Teng, Chuanhui Xu, Johnston G. X. Tang, Kok Ooi Kong, Stanley Angkodjojo, Wei-Rui Goh, Tyng Yu Chuah, Nur Emillia Roslan, Thaschawee Arkachaisri, Kai Liang Teh, Melonie Sriranganathan, Teck Choon Tan, Kee Fong Phang, Qai Ven Yap, Yiong Huak Chan, Peter P. M. Cheung, Manjari Lahiri
Summary: A national retrospective cohort study found a moderately high rate of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination, but also improvement in several patients. Severe flares and hospitalization were rare. Thus, vaccination remains safe and highly recommended.
JOURNAL OF AUTOIMMUNITY
(2023)
Correction
Rheumatology
Ying-Ying Leung, Tatiana Korotaeva, Liliana Candia, Susanne Juhl Pedersen, Wilson Bautista Molano, Eric M. Ruderman, Radjesh Bisoendial, Rodolfo Perez-Alamino, Wendy Olsder, Burkhard Moller, Simeon Grazio, Tania Gudu, Girish M. Mody, Carlos Pineda, Helena Raffayova, Sherry Rohekar, Claudia Goldenstein-Schainberg, Sergio R. Gutierrez Urena, Julio Cesar Casasola Vargas, Bhowmik Meghnathi, Roopa Prasad, Pascal Richette, Jose Roberto S. Miranda, Nikolas Malliotis, Ulla Lind-Qvist, David Simon, Amara Ezeonyeji, Enrique R. Soriano, Oliver FitzGerald
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Marlene Sousa, Ennio Lubrano, Josef S. Smolen, Clemence Gorlier, Maarten de Wit, Laura C. Coates, Umut Kalyoncu, Adeline Ruyssen-Witrand, Ying-Ying Leung, Rossana Scrivo, Juan D. Canete, Penelope Palominos, Sandra Meisalu, Andra Balanescu, Uta Kiltz, Sibel Zehra Aydin, Inna Gaydukova, Emmanuelle Dernis, Bruno Fautrel, Ana-Maria Orbai, Laure Gossec
Summary: This study aimed to explore patient-defined flares in psoriatic arthritis (PsA) and compare them to an increase in disease activity in psoriatic arthritis (DAPSA). The validity of a patient-reported flare question was also analyzed. The results showed that patient-reported flares were associated with disease activity and symptoms, and there was moderate agreement between patient and physician definitions of worsening.
Editorial Material
Rheumatology
Ying-Ying Leung, Arthur Kavanaugh, Christopher T. Ritchlin
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Ling Xiang, Sungwon Yoon, Andrea H. L. Low, Ying Ying Leung, Warren Fong, Tang Ching Lau, Dow Rhoon Koh, Julian Thumboo
Summary: This study explores the applicability of social cognitive theory (SCT) in improving symptom appraisal and help-seeking among patients with autoimmune rheumatic diseases (ARDs). Semi-structured interviews were conducted with 33 ARD patients and the transcripts were coded using SCT as the framework. The study found that behavioral capacity and self-efficacy were lacking in symptom interpretation, leading to delayed help-seeking. Possible approaches to address this include education to improve behavioral capacity and self-efficacy and enhance expectations, observational learning, reinforcements, and reciprocal determinism.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Warren Fong, Ting Hui Woon, Li-Ching Chew, Andrea Low, Annie Law, Yih Jia Poh, Siaw Ing Yeo, Ying Ying Leung, Margaret Ma, Amelia Santosa, Kok Ooi Kong, Chuanhui Xu, Gim Gee Teng, Anselm Mak, Sen Hee Tay, Tyng Yu Chuah, Nur Emillia Roslan, Stanley Angkodjojo, Kee Fong Phang, Melonie Sriranganathan, Teck Choon Tan, Peter Cheung, Manjari Lahiri
Summary: This study investigated the prevalence and factors associated with disease flares post COVID-19 mRNA vaccination in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). The results showed that about one-fifth of patients experienced a disease flare after vaccination, but most flares were non-severe. Patients with active disease prior to vaccination, especially those with RA, should be closely monitored for disease flares.
ADVANCES IN RHEUMATOLOGY
(2023)
Article
Rheumatology
Ying Ying Leung, Lihi Eder, Ana-Maria Orbai, Laura C. Coates, Maarten de Wit, Josef S. Smolen, Uta Kiltz, Penelope Palominos, Juan D. Canete, Rossana Scrivo, Andra Balanescu, Emanuelle Dernis, Sandra Meisalu, Martin Soubrier, Umut Kalyoncu, Laure Gossec
Article
Rheumatology
L. Xiang, A. H. L. Low, Y. Leung, W. Fong, W. Gan, N. Graves, M. Gandhi, J. Thumboo
Summary: Reduced work productivity is common in patients with inflammatory arthritis and osteoarthritis, but the improvements in work productivity and their association with health status were not well characterized. This study found that patients with inflammatory arthritis showed greater improvements in work productivity compared to those with osteoarthritis in the first six months after diagnosis, suggesting the importance of aiming for greater improvements in work and health status for patients with inflammatory arthritis.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Lars E. Kristensen, Bruce Strober, Denis Poddubnyy, Ying-Ying Leung, Hyejin Jo, Kenneth Kwok, Ivana Vranic, Dona L. Fleishaker, Lara Fallon, Arne Yndestad, Dafna D. Gladman
Summary: This study analyzed the association between baseline cardiovascular disease risk and the occurrence of major adverse cardiovascular events and malignancies in tofacitinib-treated patients with PsA and PsO. The results showed that patients with increased ASCVD risk and baseline metabolic syndrome had higher incidence rates for MACE and malignancies. It highlights the importance of assessing CV risk and enhancing cancer monitoring in patients with PsA and PsO.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2023)
Article
Rheumatology
T. C. Tan, L. Chandrasekaran, Y. Y. Leung, R. Purbojati, S. Pettersson, A. H. L. Low
Summary: Using metagenomic sequencing, this study reveals distinct alterations in microbiota profiling among Asian SSc patients.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)